MicroRNAs -23b and 27b induction analysis in high grade bladder urothelial Carcinoma cells: in vitro study

• Grant number: 21/08439-8
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: December 01, 2021
• End date: November 30, 2022
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Sabrina Thalita dos Reis Faria
• Grantee: Guilherme Calderelli Nebó
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Bladder cancer is the most common cancer that affects the urinary system in the United States, responsible for thousands of deaths in both men and women. In Brazil alone, according to the Instituto Nacional de Câncer (Inca), 10,640 new cases were predicted in the year 2020. Thus, the search for new treatment methods to combat the disease, especially regarding muscle-invasive carcinoma, since it is the most lethal form of the neoplasm, is necessary. MicroRNAs are small non-coding protein RNAs that regulate several cellular processes besides interfering directly and indirectly in oncogenic processes. The miRs -23 and -27b are described in several studies in bladder cancer, and their expression is underexpressed, thus by increasing the level of their expression in bladder cancer affected cells, we postulate that potentially this modulation may present a protective role inhibiting or attenuating tumor progression. To stimulate the expression of miRs-23b and 27b, we will use the transfection technique, Lipofectamine RNAiMax. The extraction of microRNA molecules will be performed with the use of isolation kits. Through a reverse transcription, the complementary DNA of these microRNAs will be obtained, and with a real-time PCR, the expressions of the studied microRNAs will be obtained. Finally, the wound healing assay will be used to analyze the characteristics of cell migration. Through this work, we intend to increase the expression of these microRNAs in a high-grade bladder cancer cell line in vitro to evaluate a possible therapeutic role of these two molecules in high-grade urothelial carcinoma.(AU)